Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about COAG, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Sutacimig | Thrombasthenia | Phase 3 · NCT07935356 | Recruiting |
| HMB-001 | Glanzmann Thrombasthenia | Phase 1/2 · NCT06211634 | Active not recruiting |
| HMB-002 (Part A) | Von Willebrand Disease (VWD) | Phase 1/2 · NCT06754852 | Recruiting |
| HMB-002 with Concomitant Factor Concentrate… | Von Willebrand Disease (VWD) | Phase 1/2 · NCT06754852 | Recruiting |
| HMB-003 | Healthy Adult Participants | Phase 1 · NCT07798505 | Recruiting |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
COAG holds $441.6M in cash and short-term investments (as of Sep 30, 2026) and burns about $25.5M/quarter from operations, an estimated runway of 52 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 0 · Low
We believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements into 2029.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when COAG files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| AI DEN-MAB LLC 10% owner |
Insider | 4,876,344 | 10.44% | 2026-05-04 |
| FMR LLC | Institution (13G, 5%+) | 4,871,850 | 10.43% | 2026-10-30 |
| Novo Holdings A/S 10% owner |
Insider | 4,180,550 | 8.95% | 2026-06-30 |
| Capital International Investors | Institution (13G, 5%+) | 3,603,876 | 7.71% | 2026-06-30 |
| Deep Track Capital, LP | Institution (13G, 5%+) | 3,600,996 | 7.71% | 2026-05-01 |
| Behzad Aghazadeh | Institution (13G, 5%+) | 3,298,236 | 7.06% | 2026-06-30 |
| Sofinnova Crossover II SLP | 5%+ holder (13G) | 2,511,212 | 5.37% | 2026-06-30 |
| Raymond Debbane | 5%+ holder (13G) | 2,366,235 | 5.06% | 2026-08-03 |
| RA CAPITAL MANAGEMENT, L.P. 10% owner |
Insider | 354,938 | 0.76% | 2026-06-15 |
| Mads Nikolaj Behrndt-Eriksen Chief Financial Officer and General Mana · +244,222 options |
Insider | 36,520 | 0.08% | 2026-04-30 |
| John Maraganore Director · +107,338 options |
Insider | 35,948 | 0.08% | 2026-01-29 |
Share count 46,730,608 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for COAG and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →